Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Hims & Hers is getting $1 billion of rocket fuel.

Hims & Hers Health shares have surged 17.4% this week. The company reported strong first-quarter earnings late Monday.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month.

The company makes immunoglobulin products using donated plasma.

Hims & Hers Health Inc (NYSE:HIMS) shares are falling Thursday morning after the company announced a proposed convertible senior notes offering.

This isn't just any growth stock.

Hims & Hers Health shares have surged 32.4% since Tuesday's session open. The stock is gaining following a standout first-quarter earnings report released late Monday.

Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs.

Hims & Hers is on fire right now.

Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' expectations on revenue, EPS, and EBITDA. Revenue more than doubled from last year driven by higher monthly spending per subscriber and a broader product mix tailored to personalized health needs. While subscriber growth slowed to 38% year over year, average revenue per user climbed over 50%, indicating deeper wallet share from existing customers and more engagement with premium offerings. On the other hand, revenue guidance was softer than anticipated. Still, we think this was a decent quarter.

Good news for Hims & Hers stock spooks Lilly and Novo investors.

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q1 CY2025, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $540 million was less impressive, coming in 2.4% below expectations. Its non-GAAP profit of $0.30 per share was 32.2% above analysts’ consensus estimates.

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum.

Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter earnings on Monday after the market closed.